Mass General Brigham Salem Hospital, Salem, MA.
Division of Hematology/Oncology, Mayo Clinic, Rochester, MN.
JCO Glob Oncol. 2024 Aug;10:e2400254. doi: 10.1200/GO-24-00254.
The study assesses the current state of global oncology (GO)/hematology training opportunities in US fellowship programs.
We developed a comprehensive survey of 64-Likert multiple-choice and open-ended questions. The survey was electronically distributed to fellowship program leaders at Accreditation Council for Graduate Medical Education-accredited adult hematology/oncology fellowships. Program directors received three reminders after which survey was sent to assistant program directors or division heads for programs not represented.
A total of 171 programs were eligible for the survey. We received 42 (24.6%) responses; 40 were included in the analysis, and two were excluded for declined consent and incomplete responses. The programs include large academic (81.6%) and community hospitals (10.5%). Of the respondents, 18 (48.6%) reported offering some opportunities for global health training, and half reported interest among current fellows. Most programs (29, 82.9%) had three or fewer faculty engaged in GO research. Institutional training grants were available in 15 (39.5%) programs, of which six (40%) allowed for global health research. Of the 18 programs offering global health training activities, most (15, 83.3%) report less than a quarter of their trainees currently participate in GO experiences. The most commonly perceived barriers to GO opportunities include competing priorities (85.3%) and lack of faculty mentors with GO-related experience (82.4%). Conversely, the most commonly perceived facilitators include established partnerships outside the United States (97.0%) and dedicated institutional funding (93.9%).
Our survey demonstrates that although there is significant interest among fellowship trainees, a minority of the fellowship programs offer GO opportunities. Providing GO opportunities would require programs to establish partnerships with institutions outside the United States and to have systematic approaches of addressing other barriers, including enhancing funding and mentorship.
本研究评估了美国研究员课程中全球肿瘤学(GO)/血液学培训机会的现状。
我们开发了一项包含 64 个李克特量表多项选择题和开放式问题的综合调查。该调查通过电子方式分发给经研究生医学教育认证委员会(Accreditation Council for Graduate Medical Education)认证的成人血液学/肿瘤学研究员课程的研究员课程负责人。在发出三个提醒后,未回复的课程将调查发送给助理课程主任或未代表的课程部门负责人。
共有 171 个课程符合调查条件。我们收到了 42 份(24.6%)回复;其中 40 份被纳入分析,另外两份因拒绝同意和回复不完整而被排除。这些课程包括大型学术(81.6%)和社区医院(10.5%)。在受访者中,有 18 人(48.6%)报告提供了一些全球卫生培训机会,有一半的人报告目前研究员对此感兴趣。大多数课程(29 个,82.9%)只有三到四位教师从事 GO 研究。15 个(39.5%)课程提供机构培训赠款,其中 6 个(40%)允许进行全球卫生研究。在提供全球卫生培训活动的 18 个课程中,大多数(15 个,83.3%)报告目前只有不到四分之一的学员参加 GO 体验。GO 机会最常被认为的障碍包括优先级竞争(85.3%)和缺乏具有 GO 相关经验的教师导师(82.4%)。相反,最常被认为的促进因素包括与美国以外的机构建立合作伙伴关系(97.0%)和专用机构资金(93.9%)。
我们的调查表明,尽管研究员学员对此有浓厚兴趣,但只有少数研究员课程提供 GO 机会。提供 GO 机会将需要课程与美国以外的机构建立合作伙伴关系,并采取系统的方法解决其他障碍,包括加强资金和指导。